Polpharma Pursues Tysabri Through Antelope Trial
First Patients Recruited In Poland
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.
You may also be interested in...
FDA Reviews Natalizumab For Sandoz And Polpharma
Sandoz and Polpharma have quickly followed news of a European natalizumab filing with confirmation that the proposed biosimilar version of Tysabri has also been accepted for review by the US Food and Drug Administration.
Polpharma Celebrates Being First With Natalizumab In Europe
Polpharma Biologics has claimed the first biosimilar natalizumab filing in Europe, after the European Medicines Agency accepted the firm’s marketing authorization application for review.
What’s Next? Five Things To Look Out For In August
In the month ahead, Teva will see a key management change, Polpharma is set to wrap up a landmark Phase III biosimilar study and financial results for all manner of industry participants will continue to trickle out.